Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite.

By I. Mueller, M. Galinski, J. Baird, J. Carlton, D. Kochar, P. Alonso, H. D. del Portillo. Lancet. Infectious Diseases (Print), 2009

648 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination (2011, background): “9 billion people are at risk for vivax malaria (179), with an estimated 80 million to 300 million clinical cases annually (296).”
Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax (2011, background): “The elimination strategies are however limited and confounded by emergence of multidrug resistant isolates and relapse from dormant hypnozoites stages at varying time intervals after the initial infection and there have not been available any optimal chemotherapeutic agents to combat against these s”
Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction (2012, background): “vivax has a long dormant liver stage, lasting months in some cases, and poses a significant threat to the global health (2).”
Effective Preparation of Plasmodium vivax Field Isolates for High-Throughput Whole Genome Sequencing (2013, positive): “Rising levels of multidrug resistance and severe disease have refocused efforts to better understand and control vivax malaria [2–8].”